Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — DNB Carnegie Nordic Healthcare Conference 2025
21 slides from Oncoinvent Asa's conference presentation, Nov 25, 2025
Slide 1: Transforming cancer care through direct alpha therapy
Oncoinvent Transforming cancer care through direct alpha therapy DNB Healthcare conference 25 November 2025
Slide 2: A unique radiopharmaceutical opportunity
SUMMARY A unique radiopharmaceutical opportunity 1 Targeted, non-biological, receptor independent mode of action with alpha emitter 2 Signals of efficacy: potential game changer in ovarian and colorectal cancers 2 3 In Phase 2 in ovarian cancer 3 4 High unmet need and limited competition 4 5 Develop
Slide 3: Peritoneal metastases - urgent need for novel treatments
UNMET MEDICAL NEED Peritoneal metastases - urgent need for novel treatments • Peritoneal metastases arise from many different primary cancers • Only treatment option with curative intent is surgery, effect of systemic therapy is limited • Surgery leaves behind micro- metastases causing disease progr
Slide 4: The main cause of death in ovarian cancer
UNMET MEDICAL NEED The main cause of death in ovarian cancer • The majority of patients experience disease recurrence • Recurrences are almost exclusively confined to the peritoneum • Local control in the peritoneum is key to improving life expectancy • FDA Fast Track Lengyel Am J Pathol. 2010 Sep;
Slide 5: Radspherin® - alpha therapy targeted to and retained in the peritoneum
TREATMENT CONCEPT Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® • Combining alpha-emitting 224Ra with CaCO3 microparticles • Half-life 3.6 days • Therapy with depot effect - 75% of radiation dose delivered the first week • Shelf life 8 days allowing for centraliz
Slide 6: Radspherin® - alpha therapy targeted to and retained in the peritoneum
TREATMENT CONCEPT Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® How does it work? • Combining alpha-emitting 224Ra with • Delivering a high dose of alpha-radiation CaCO3 microparticles directly to the peritoneum through an in- dwelling catheter • Half-life 3.6 da
Slide 7: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Interim Final Colorectal Final Ph 2 Ovarian N = 96 Interim Interim Final Completed Upcoming milestones 7
Slide 8: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Interim Final Colorectal Final Ph 2 Ovarian N = 96 Interim Interim Final Completed Upcoming milestones 8
Slide 9: Radspherin® - phase 1 study in ovarian cancer
Radspherin® - phase 1 study in ovarian cancer RAD-18-001: in patients after secondary debulking 4 clinical sites: surgery of platinum-sensitive recurrent ovarian cancer • Oslo, Norway(PI: Yun Wang) • single-arm open label study • Leuven, Belgium (PI: Els van Nieuwenhuysen) • 3 + 3 dose-escalation (1
Slide 10: Ovarian cancer: Preventing disease progression
PHASE 1 RESULTS Ovarian cancer: Preventing disease progression 24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates Recurrence rate RAD-18-001 “These final results are truly encouraging, suggesting that 10 % 30 % Radspherin® could help delay disease progression and off
Slide 11: Ovarian cancer: Preventing disease progression
PHASE 1 RESULTS Ovarian cancer: Preventing disease progression 24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates Recurrence rate RAD-18-001 Historical controls “These final results are truly encouraging, suggesting that 10 % 30 % Radspherin® could help delay disease
Slide 12: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Interim Final Colorectal Final Ph 2 Ovarian N = 96 Interim Interim Final Completed Upcoming milestones 12
Slide 13: Colorectal cancer: final phase 1/2a data confirm peritoneal control
PHASE 1 RESULTS Colorectal cancer: final phase 1/2a data confirm peritoneal control Topline 18-months data of 36 patients receiving 7 MBq dose vs historical recurrence rates Peritoneal recurrence rate "It’s highly encouraging to see Radspherin® Historical control patients treated with Radspherin ach
Slide 14: Controlling peritoneal disease may significantly improve survival in colorectal cancer
Controlling peritoneal disease may significantly improve survival in colorectal cancer First disease recurrence after treatment 1 Impact of site of first site of recurrence 1 1/3 peritoneal only Median overall survival - from the time of recurrence: 1/3 combined • After distant metastasis only: 44 m
Slide 15: Strong safety profile demonstrated in the completed phase 1/2a studies
PHASE 1/2A RESULTS Strong safety profile demonstrated in the completed phase 1/2a studies in ovarian and colorectal cancer Well tolerated and safe • No dose limiting toxicity to use • Only two SAEs possibly related to Radspherin* No evidence of systemic • Radiation dose retained in the peritoneal ca
Slide 16: Near-term significant milestone
Near-term significant milestone Phase 2 • 2H26: First randomized interim data ovarian cancer • 2028: Final data • Final 24 months data Phase 1 • 10 patients 7 MBq ovarian cancer • October 2025 • Final 18 months data Phase 1/2a • 36 patients 7 MBq colorectal cancer • June 2025 16
Slide 17: Phase 2 study in ovarian cancer – enrollment on track
PHASE 2 PROGRAM – OVARIAN CANCER Phase 2 study in ovarian cancer – enrollment on track 6 centers active – more sites to be included Patients PFS • with peritoneal pPFS SoC+ Radspherin Assessment OS metastases (60 patients) every 3 TFST • after neoadjuvant Randomised Safety run-in 2:1 months up to TS
Slide 18: Pipeline in one product - broad clinical application
MARKET OPPORTUNITY Pipeline in one product - broad clinical application • Peritoneal metastases arise from many Extraperitoneal Intraperitoneal different cancers origin origin Lung cancer Cholangiocarcinoma • Radspherin® is a receptor-independent Breast cancer Gastric cancer treatment: Malignant mel
Slide 19: In-house GMP pilot plant with attractive capabilities
MANUFACTURING AND SUPPLY In-house GMP pilot plant with attractive capabilities Oncoinvent has in-house GMP 224Ra produced from 228Th, which Microparticles and finished goods production capability has multiple sources produced in-house • Capacity of ~200 doses Radspherin annually, outsourcing and sca
Slide 20: Radiopharmaceutical expertise at all levels
Radiopharmaceutical expertise at all levels Scientific founders Roy Larsen Øyvind Bruland Management Oystein Soug Gro Hjellum Anne-Kirsti Aksnes Kari Myren Tore Kvam Kristine Lofthus Stian Brekke Chief Executive Officer Chief Operations Officer Chief Clinical Officer Chief Medical Officer Chief Fina
Slide 21: A unique radiopharmaceutical opportunity
SUMMARY A unique radiopharmaceutical opportunity 1 Experienced team with track record from radiopharmaceutical developments and exits 1 2 Targeted, non-biological, receptor independent lower risk mode of action 2 3 Compatible 3 with established treatment regimes - adds well to existing patient flow
Oncoinvent — DNB Carnegie Nordic Healthcare Conference 2025 on 6ix